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Purpose. Despite the latest technological advances in radiotherapy, cancer control is still challenging for several tumour sites. The
survival rates for themost deadly cancers, such as ovarian and pancreatic, have not changed over the last decades.The solution to the
problem lies in the change of focus: from local treatment to systemic therapy. The aim of this paper is to present the current status
as well as the gaps in radiotherapy and, at the same time, to look into potential solutions to improve cancer control and survival.
Methods. The currently available advanced radiotherapy treatment techniques have been analysed and their cost-effectiveness
discussed. The problem of systemic disease management was specifically targeted. Results. Clinical studies show limited benefit
in cancer control from hadron therapy. However, targeted therapies together with molecular imaging could improve treatment
outcome for several tumour sites while controlling the systemic disease. Conclusion. The advances in photon therapy continue to
be competitive with the muchmore expensive hadron therapy. To justify the cost effectiveness of proton/heavy ion therapy, there is
a need for phase III randomised clinical trials. Furthermore, the success of systemic disease management lies in the fusion between
radiation oncology technology and microbiology.
1. Introduction
The AACR Cancer Progress Report (2011) shows that, in the
USA from 1990 to 2007, death rates from all cancers dropped
22% in men and 14% in women. More than 68% of adults live
five years ormore after diagnosis, up from 50% in 1975. For all
pediatric cancers, the five-year survival rate is 80%, compared
with 52% in 1975. However, the poor survival rates from the
most deadly cancers: pancreatic, ovarian, and glioblastoma
multiforme (GBM) have not changed to this date.
Keyhole and robotic surgery are major developments in
the surgical management of cancer. Patients suffer reduced
hospitalisation, but have concomitant costs decreased?
Patient quality of life has undoubtedly improved, but are
patients living longer?
Pediatric leukaemia is no longer a death sentence and
testicular cancer responds well to cisplatin therapy. But
most chemotherapy applications are palliative in intent and
associated with complications and reduction in the quality of
life.
External beam radiotherapy has developed over 100 years
from low energy X-rays, through Cobalt-60 gamma rays
to linear accelerators producing ever-increasing photon and
electron energies. Nowadays, external photon beams can be
delivered to precise, irregular targets via many modalities:
three-dimensional conformal (3DCRT), intensity modulated
(IMRT), and image-guided (IGRT) radiotherapies. As excel-
lent as these modalities are, they are directed not so much
to the cancers that cannot be controlled but to those that
can be. As such, the local control and survival achieved
with these technologies do not correlate with the increasing
cost of external beam radiotherapy (EBRT) (Figure 1). Still,
advances in photon radiotherapy continue to be competitive
with themuchmore expensive high energy proton and heavy
ion therapy, used for their exceptional advantage in sparing
critical tissues.











Figure 1: Cost-benefit diagram of current radiotherapy modalities.
On the imaging side, the development of computed
tomography (CT), single photon emission tomography
(SPECT), positron emission tomography (PET), magnetic
resonance imaging (MRI), and functional MRI (fMRI) has
been of immense importance in developing our ability to
see into our bodies and examine function. Tumours can
be identified down to a few mm in diameter with MRI
and to 4-5mm for functional images with PET. Current in
vivo imaging techniques continue to resolve smaller and
smaller tumours but can never resolve subclinical disease,
by definition, nor tell us where micrometastases lie (see
Figure 2).
Without doubt, the oncologist’s job of managing cancer
has been made much easier and more certain, but has
this translated into improved prognoses for cancer patients?
The evidence presented by the AACR suggests that the
answer is in the affirmative, although early detection may
be responsible for much of the improvement. External beam
radiotherapy has improved markedly in terms of targeting
well-defined volumes and achieving local control but can
never eliminate systemic disease.
The “war on cancer” analogy is often used. But like the
21st century wars, the apparent initial success is masked
by the long-term failure to control systemic disease. Few
primary cancers are fatal, GBM being the standout, and
it is not the primary tumour that determines outcome. It
is the cancer cells released from the tumour that invade
the vascular and lymphatic systems that eventually lead to
multiple metastases and organ failure as normal functional
tissues are crowded out by the ever populating cancer cells.
Therefore, disseminated disease is the primary cause of
cancer death. Yet this objective has been overlooked during
the development of modern radiotherapy techniques that are
focused on external beam radiotherapy.
On top of this is the rapidly developing cost of the
management of cancer. Cancer causes the highest economic
loss of all of the 15 leading causes of death worldwide. The
World Health Organisation (WHO) note that the economic
toll from cancer is nearly 20 percent higher than heart
disease, the second leading cause of economic loss ($895
billion and $753 billion, resp.). Health budgets in developed
countries are continually expanding and constrained by
limited resources. But cost-benefit analyses to determine
whether the increased cost of treatment achieves improved
outcomes remain unknown. Perhaps the classic example is
in the treatment of primary prostate cancer where surgery,
brachytherapy, external beam photon, and proton therapies
are used, all achieving similar efficacy and complications but
at very different capital and running costs.
The developed nations’ investment in cancer research has
been growing exponentially, and the 2012 budget for the US
National Cancer Institute alone will be totalling nearly 6
billion US dollars [1, 2].
For rural populations, cancer is often diagnosed at the
symptomatic stage. Palliative therapy is the only course
to reduce pain and increase quality of life. As a result,
there is a need to provide low cost technologies appropriate
for the objective of palliation. Because of the continuing
shortage of trained oncologists, medical physicists, and other
professionals, telemedicine must be an essential element in
the development of radiotherapy care in rural regions.
We are therefore confronted with two distinct challenges:
(1) to manage and control systemic cancer,
(2) to provide cost-effective technologies.
2. Current Status and Gaps
2.1. External Beam Radiotherapy and Intensity Modulated
Radiation Therapy. EBRT and IMRT are the current stan-
dards of care for radiation oncology patients. IMRT is
known to be a highly conformal treatment, involving reduced
treatment margins which results in improved tumour control
and reduced normal tissue toxicity. However, the ability to
deposit a high dose into well-defined tumours is not always
desired, as too precise targeting can lead to increased local
recurrences. The biology of the tumour must determine the
clinical tumour volume (CTV) margin, not the resolution of
beam delivery. If the CTV margin cannot be fully imaged,
then this becomes themost difficultmargin to be determined.
The decision is typically based on clinical assessment of
risk, on local clinical practice, and on historical evidence
rather than the tumour spread quantified in an individual
patient. Often a uniform CTV margin is used regardless of
potential anisotropy in the microscopic tumour spread. The
extent of the CTV margin depends on information received
from imaging techniques. Such accurate, individualised CTV
determinations represent one of the problemswhere develop-
ments in diagnostic imaging (molecular imaging techniques
in particular) will improve radiotherapy treatment [3].
Other factors include problems with treatment times and
dose gradients. IMRT increases the volume of normal tissue
exposed to a low dose. However, what might have been
thought to be a negative factor could be positive, in view of
hormesis effects.
2.2. Hadron Therapy. Protons offer greatly improved and
precise dose deposition and as a result lower normal tissue
doses. But does proton therapy always give superior efficacy,
reduced complications, improved prognosis, and lower cost
therapy?While there are unique applications of proton beams








































Figure 2: Building blocks of cancer management.
that give reduced adverse events, especially for pediatric
cancers [4, 5], the answer appears to be negative. Prostate
cancer is a major application for proton machines. But
prognosis for prostate cancer is mostly set not by the primary
therapy but by the initial stage of the disease on diagnosis
[6, 7]. As such, low risk patients with PSA < 10 and Gleason
6 are very unlikely to succumb to the disease and will not be
in need of radical therapies.
Uveal melanoma (an extremely low incidence cancer)
was a long-standing application for proton therapy. However,
on the basis of an intralesional skin melanoma trial of
targeted alpha therapy [8], there is every reason to think that
intralesional injection into the uveal melanoma will not only
save the eye but could well eliminate the micrometastases
arising from the primary site that lead to patient death within
5–10 years.
There is increasing evidence that improved control of
the primary lesion, arising from the new modalities for
protons and heavy ion (C-12) beams, translates into improved
survival [9, 10]. However, care must be taken to distinguish
between survival and progression-free endpoints, which are
not necessarily correlated.
2.3. Cost Benefit of Proton, Heavy Ion, and Photon Therapy.
The major advantage of IMRT is its low capital and running
costs. While patient charges are not so much of an issue
for a well-insured patient, there is a major health issue
relating to the availability of radiotherapy to cancer patients.
Does western society need many more IMRT units or one
proton therapy facility only? Also, is proton therapy cost-
effective and is there evidence in clinical trials supporting
clinical gains of proton therapy versus conventional therapy?
If the current evidence-basedmedicine standards are used for
determination of clinical efficacy of proton therapy, it must be
concluded that the evidence is limited and mostly based on
noncontrolled studies. A Phase III clinical randomised trial
has not been conducted for proton therapy.
Several studies have been though conducted trying to
identify the cost-benefit of proton therapy and the type of
cancer patients that might benefit from proton therapy [11,
12]. Several investigations concluded that for approximately
15% of cancer patients treated with radiation therapy, proton
therapy might be cost-effective. According to Glimelius and
Montelius, “This means that one proton therapy facility
being able to yearly treat a reasonable number of patients
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(1000–2000) is motivated for a western world population
of about 10 millions. The same estimations for light ions,
however, much more uncertain, came to an estimate of 50
millions” [13].
Lodge et al. [14] conducted a systematic literature review
(comprising, 54 publications: 4 randomized controlled trials
reported in 5 publications, 5 comparative studies, and 44 case
series) on the efficacy of hadron therapy (therapies including
protons, neutrons, and light and heavy ions), concentrating
on external beam techniques. They found that there is
insufficient clinical evidence available to justify the rapid
expansion of hadron facilities as a major treatment modality
and recommended that further research into the clinical
and cost-effectiveness of hadron therapies was required. The
authors concluded, “the current literature shows that the
introduction, or significant extension, of hadron therapy as
a major treatment modality—except on aminor scale for cer-
tain rare tumours (ocular, chordomas, etc.)—into standard
clinical patient care cannot be supported by the evidence
base currently available. There are little reliable evidence-
based data available concerning the relative cost-effectiveness
of hadron therapy interventions when compared with each
other, with photon therapy, or with other cancer treatments.”
2.4. Targeted Therapy. Although not a standard of care in
radiation oncology, targeted therapies are emerging treat-
ment techniques with the ability to control systemic disease.
With advances in immunology and the development of
exquisite targeting vectors, we can now engage in targeted
imaging and therapy using the alpha, beta, and gamma
rays emitted from radioisotope labels. However, the use of
radioisotope therapy, apart from the thyroid and palliative
therapy for bone cancer, has had limited effect on survival.
Beta emitters have limited efficacy in the control of cancer,
although new radioisotopes are finding niche applications
with various targeting agents.Muchmore successful has been
the use of gamma ray emitters for imaging with SPECT and
PET.
The next generation of radioimmunotherapymay lie with
alpha-emitting radioisotopes that can selectively kill targeted
cancer cells. The field of targeted alpha therapy is slowly
gatheringmomentum, with some 10 clinical trials completed,
in operation, or at the planning stage around the world. This
fusion of biology andmedical physics suggests that we should
use the term biomedical physics much more than we do.
2.5. Tumour Site-Specific Treatment Challenges. The future
objectives for radiation therapy have to address the failures
of current therapies. Some of the site-specific treatment
challenges encountered by today’s cancer management are
mentioned below.
(i) Primary prostate cancer: there is the need to spare the
nerves and rectum to reduce incontinence, impotence
and rectal perforation.
(ii) Lung cancer: tumours can be regressed but there is the
need to eliminate subclinical metastases.
(iii) Glioblastoma multiforme: it is fatal in the primary
state, we need to improve prognosis by eliminating
subclinical disease in the brain by extravascular deliv-
ery.
(iv) Metastases to the brain: they are invariably a fatal stage
of cancer which requires elimination of subclinical
metastases by vascular delivery.
(v) Uveal melanoma: primary treatment needs to be
integrated with inhibition of lethal liver metastases.
(vi) Advanced head and neck cancer: it has poor outcome
despite the multidisciplinary treatment approach.
Around 80% of head and neck cancer patients over-
express the epidermal growth factor receptor (EGFR)
which is linked to poor prognosis. Targetedmolecular
therapy against EGFR could play a pivotal role as
adjunct therapy.
(vii) Pancreatic cancer: it is fatal in the primary state
due to late detection. There is a need to improve
prognosis by targeted immunotherapy against EGFR.
While patients with mutated EGFR might benefit
from Erlotinib (an EGFR inhibitor), the side effects
limit the efficacy of the drug. Tumour infiltration and
liver failure are ultimately the fatal stage. Another
approach is to use systemic alpha therapy against uPA
and/or MUC1 receptors [15].
(viii) Pretesting for patient radiosensitivity could avoid
overdosing of normal tissue in sensitive patients and
underdosing of the tumour in insensitive patients.
These problems relate to systemic cancer therapy as well as
local therapy. Improved spatial dose resolution is important
for tumours, but it is the ability to kill subclinical cancer cells
that has become the issue. The main problems to be solved
regarding systemic cancer therapy are summarised as follows.
(i) Micrometastases may be in the G0 phase and outside
the cell cycle; as such these cells are insensitive to
chemo- and radiotherapy and are best treated by high
LET radiation.
(ii) Normal tissue radiosensitivity for high LET radiation
needs to be investigated.
(iii) Systemic agents must target cancer cells via the vas-
cular and/or lymphatic systems.The tumour capillary
permeability becomes an important determinant as
to whether the targeting agent can diffuse into the
extravascular space.
(iv) Monitoring of systemic therapy via sequential periph-
eral blood analyses of circulating cancer cells.
(v) Tumour dormancy and factors responsible for inter-
patient variability. The mechanisms behind cancer
dormancy need to be elucidated and therapeutic
targets identified. The state of dormancy needs to be
indicated by biomarkers to predict outcome.
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3. Current Solutions and Their Limitations
Improved treatment efficacy and/or reduced normal tissue
toxicity could arise from simple changes to protocols or to
complex systemic therapies. Advances in hadron therapy, tar-
geted and molecular therapies, and well-designed predictive
assays for both tumour andnormal tissuemight be the answer
to the problems raised above.
3.1. Hadron Therapy
3.1.1. Protons and Heavy Ions. The biophysical and radiobio-
logical properties of heavy ions render them suitable for the
management of complex anatomical structures and radiore-
sistant tumours. For example, unresectable osteosarcomas
are good candidates for proton/carbon ion treatment as the
dose necessary for curative radiotherapy is too large to be
deliverable with photon therapy. Also, these tumours are
often located in close proximity to radiosensitive organs such
as the brain; spinal cord, or pelvis, therefore conventional
treatment is not suitable for their management [16].
The Japanese research group from theResearchCentre for
Charged Particle Therapy National Institute of Radiological
Sciences, Chiba [17–19], have demonstrated the efficiency of
carbon ion radiotherapy on several tumour sites and types
such as locally advanced head and neck tumours; early stage
NSCLC and locally advanced NSCLC; unresectable locally
advanced bone and soft tissue sarcomas; locally advanced
hepatocellular carcinomas; locally advanced prostate carci-
nomas; chordoma and chondrosarcoma of the skull base and
cervical spine; malignant gliomas and oesophageal cancer.
While protons do not offer clinical advantage to certain
tumour sites when compared to photon treatment, for ocular
tumours Lodge et al. concluded that proton therapy results
in approximately 90% eye preservation rates and 50% vision
preservation after 5 years. The clinical superiority of protons
in ocular radiotherapy was particularly demonstrated for
larger tumours and specific locations in the eye, with the
benefit dropping off for smaller lesions (e.g., <4mm).
Table 1 (modified from [14]) provides a summary of
comparative clinical results for proton and ion therapy with
conventional photon therapy. In base of skull chordomas,
both protons and ions appear to provide superior results
to photon therapy. In other central nervous system (CNS)
tumours the results of photons were found to be similar to
those reported for protons and ions.
There were no definitive conclusions on the relative cost-
effectiveness/gains of protons and heavy ions compared to
photons for head and neck cancer, gastrointestinal tumours,
non-small cell lung cancer, sarcomas, cancer of the uterine
cervix, and bladder cancer. Similarly, for the case of the locally
advanced prostate cancer, both photons and protons resulted
in similar therapeutic gains. Furthermore, while effective on
well-localized tumours, hadron therapy is not a solution for
the management of systemic disease.
As of 2010, there are 31 active proton therapy centers, 2
heavy ion facilities, and approximately 12 neutron therapy
centers in operation [20]. There are as many as 22 new,
planned, or proposed proton therapy centers, some of which
are already under construction. In some of these new centers
it is proposed to combine both proton and heavy ion therapy
facilities.
The capital cost of a proton therapy facility is around
$140 million for a large facility with four treatment rooms,
reducing to approximately $50 million for a minimal facility.
The cost per patient treatment is around $20–25,000. Stan-
dard radiotherapy is exceptionally cheap and perhaps should
not be used for comparative purposes. One benchmark
is $50,000 per life-year saved, but it is difficult to show
that proton therapy actually saves lives. Costs for other
therapeutic modalities are surgery ∼$15,000, chemotherapy
∼$30,000, and bone marrow transplant ∼$70,000. However,
these modalities are not associated with high capital costs.
3.1.2. Neutrons. Neutrons have been trialled in the past
for various malignancies due to their high LET proper-
ties. Radioresistant, hypoxic, and/or slowly-growing tumours
were found to be good candidates for neutron therapy.
Although neutrons can be twice as toxic to hypoxic cancer
cells as photons for the same absorbed dose (the oxygen
enhancement ratio of neutrons is around 1.6 compared to
OER = 3 for photons), the supporting experimental evidence
for superior efficiency of neutrons as compared to photons
on hypoxic tumours remains inconclusive. Salivary gland
tumours and radioresistant sarcomas are probably the only
cancers which were shown to benefit from fast neutron
treatment.
Boron neutron capture therapy involving epithermal (for
deep seated tumours) or thermal neutrons (for superficial
tumours) showed promising results for a limited number of
tumour sites such as the brain (glioblastoma multiforme),
melanoma, and head and neck [21–23]. While the high RBE
of epi/thermal neutrons implies a good outcome, the success
of the method depends on the selective uptake of boron
compounds by cancer cells.
In postsurgical glioblastomas the problem arises in the
inability to kill cancer cells as they infiltrate in the hyaluronic
acid flow through the perivascular space in the brain. For
external beam radiotherapy, the therapeutic gain is less
than 1, as radiation damages normal tissue cells more than
the cancer cells. If high LET radiation is used, any gains
from reducing cell cycle effects are lost by delayed radiation
necrosis when quiescent endothelial and other cells undergo
mitotic cell death. A solution to this problem would be to
selectively target theGBMcells and kill themwith short range
cytotoxicity. BNCT had some success with this process, with
a boron-10 compound being taken up by the cancer cells and
activated in situ by an external beam of neutrons. However,
bioavailability could be a limiting factor in controlling the
cancer.
3.2. Targeted Therapies. The next major breakthrough in
cancer management lies in the fundamental biology and
genetics knowledge to address the aforementioned problems
rather than further improvements of physical technology
which can never reach the required resolution.
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Table 1: Comparative clinical results for proton and heavy ion therapy with conventional therapy (modified from [14]).
Tumour site Proton therapy Heavy ion therapy
Studies/Patients Results Studies/Patients Results
Head and neck 2/62 Not conclusive 2/65 Not conclusive
Prostate 3/1751 Similar 4/201 Not conclusive
Eye 10/7708 Superior 2/1343 Similar to protons
Lung 3/156 Not conclusive 3/205 Similar to stereotactic radiotherapy
CNS 10/839 Similar 3/405 Similar to protons
Gastro-intestinal 5/369 Not conclusive 2/73 Not conclusive
Pelvic 3/80 Not conclusive 2/49 Not conclusive
Targeted alpha therapy is a novel high LET therapeutic
approach which incorporates the essential elements for can-
cer therapy: a targeting molecule that fixes to membrane-
bound molecules on the surface of cancer cells, and a
cytotoxic radiation that deposits a large fraction of energy
into the targeted cell.
While alpha therapy is still a work in progress, develop-
ments are being made in translating from preclinical studies
to clinical trials. Alpha therapy is demonstrating efficacy in
leukaemias as well as in glioblastomas, where results from
intracavity administration are very promising, with a 52-
week median survival.The use of peptides for targeting GMB
is also under investigation [24]. However, the promise of
targeted alpha therapy is greatly extended by the development
of tumour antivascular alpha therapy (TAVAT) for solid
tumours [25]. Metastatic melanoma results show surprising
tumour regressions at doses very much below the maximum
tolerated dose and, if further research is successful, could
change the prognosis for end-stage cancers [26].
3.3. Molecular Imaging. Understanding of cancer genetics
and biochemistry will improve with advances in molecular
imaging, combining physics, chemistry, biology, and tech-
nology. In particular, developments in fluorescent imaging
enable us to observe many cellular and subcellular processes
in vivo. In this technique a fluorescent protein is fused
with a cell protein/gene to be investigated. The composite
protein/gene is inserted into the cell of interest. The cell
gene/protein then performs its function while the attached
fluorescent protein identifies the position of the gene within
the cell by emitting fluorescent light [27].
The research into the so-called cell penetrating imaging
probes (i.e., cell penetrating peptides or CPP)made visualiza-
tion of biochemical processes in cells possible.These peptides
can translocate (through the cell membrane) covalently
attached “cargo” (i.e., molecule of interest) into a mammalian
cell without requiring specific receptors.
As for the patient tumour imaging, due to signifi-
cant absorption of fluorescent light this modality can only
be used for very superficial dermatological tumours or
tumours/tissues accessible via endoscopy. Another applica-
tion involves tumour cell illumination during surgery thus
enabling more accurate determination of tumour margins.
The principle of molecular imaging is also applicable
to molecular therapy. A large number of different cargo
molecules have been successfully delivered inside cells using
cell penetrating peptides including proteins, liposomes, and
nanoparticles [28]. Peptides have also been developed whose
uptake into cells is triggered by enzymes typical of tumours
[29]. As a result, theCPPs have potential for targeted/selective
delivery of radioactive, magnetic, nanoparticle agents and
therapeutic drugs into the cancerous tissues.
3.4. Individualized Treatment Planning. Personalized
medicine is the “leitmotiv” of the last decade’s oncology.
Three major advances are emphasized to overtake traditional
patient care in oncology: (1) the development and availability
of drugs which inhibit oncogenetic targets; (2) the
implementation of advanced technologies to allow for
prediction of treatment sensitivity and risk of recurrence;
(3) reclassification of malignant diseases with the aim of
expanding the number of orphan molecular diseases [30].
Yet, treatment differentiation among patients based on
tumour kinetodynamics, metabolism, and radiobiological
characteristics remains minimal.
It is an acknowledged fact that patients with hypoxic
tumours can gain from adjunct treatment with hypoxic
cell sensitizers or dose “painting” to allow for higher dose
deliverywith conformal radiotherapy.However, patients with
tumours which are better oxygenated should not be exposed
to hypoxic cell cytotoxins which inevitably add to the risk
of adverse events without any benefit to tumour control.
Similarly, those patients that present with highly proliferating
tumours were proven to gain from accelerated radiotherapy
and cell cycle-specific chemotherapy, whereas patients having
tumours with slow cell turnover show clinical advantage
when treated with conventionally fractionated radiotherapy
and cycle nonspecific chemotherapy. It is therefore important
to focus on individualized treatment and to develop predic-
tive assays which can reflect the outcome.
Biased and inconclusive clinical trial results due to inad-
equate patient selection have proven the need to consider
radiobiological parameters such as hypoxia, proliferative
ability, radioresistance, and of other epigenetic factors in their
design for more eloquent conclusions. However, predictive
assays trialled over the last two-three decades for oxygena-
tion status, proliferative ability, and intrinsic radioresistance
showed several limitations and they were never implemented
into clinical settings (Table 2). Assays to predict normal tissue
response to radiation will always be easier to understand,
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Table 2: Predictive assays for tumours: past, present, and future.
Primary tumour Systemic disease
Oxygen status Proliferative potential Intrinsic cellularradiosensitivity Micrometastases tumour dormancy
Past
(i) Electrodes
(ii) Biopsy (vascular density)
(iii) Endogenous markers
(iv) Exogenous markers
(i) Measurement of Tpot, TS, and
LI and correlation with outcome
(ii) Adjustment of treatment
schedule as a function of Tk
(i) Comet assay












molecular assays to detect occult
metastatic tumour cells
Future
(i) Oxygen-specific PET markers
with higher specificity (FMISO,
FAZA, FETNIM, and F-EF3,5)
(ii) BOLDMRI
(i) Proliferation-specific PET





molecular assays to detect
disseminated and circulating tumour
cells
(ii) Biomarkers to indicate the state of
dormancy
develop, and integrate in patient care than those targeting
the tumour. The challenge to “predict” treatment response
is multifaceted making it difficult to establish one complex
predictive parameter. There is though potential in tumour
parameter-specific radioisotopes used in PET to serve as
predictive assays, especially when used in combination to
provide supplementary metabolic information and diagnos-
tic specificity (such as FDG + FMISO).
Despite the fact that clinical reports strongly suggest the
routine incorporation of functional imaging such as PET/CT
in the management of several malignant sites [31–33], there
are impediments, whether related to the health system or
to physicians’ conventionality, which hinder this chance for
a better outcome. Besides the accurate staging, tumour-
specificity, and predictive ability of PET/CT, employing func-
tional/metabolic imaging techniques, also assists in the early
detection and localization of distant metastases.
However, there are limits to detection set by the tumour
size and its metabolism, such that tumours of a few mm
diameter, which contain millions of cancer cells, remain
subclinical. Further, improved staging improves manage-
ment, but may not impact on final outcome if the therapy
is inadequate. Ultimately, recurrence arises from subclinical
disease.
New tumour-specific assays might be needed to com-
plement the existing ones for a better outcome prediction.
Immunocytochemical and molecular assays for detection of
micrometastases via sequential peripheral blood analyses of
circulating tumour cells could add to the monitoring of sys-
temic therapy and to patients’ prognosis. Studies into tumour
dormancy could answer the question as to why some patients
recur soon after primary treatment and others have dormant
tumours for long after the completion of therapy? The most
commonly accepted explanation for tumour dormancy is the
failure of angiogenic switch activation, a state that maintains
the balance between proliferation and apoptosis [34]. It was
suggested that induction of growth arrest within small groups
of tumour cells (cellular dormancy) and immunosurveillance
(which prevents residual tumour cell expansion) are other
mechanisms behind cancer dormancy [35]. Molecular assays
for tumour recurrence and distant metastases are awaited to
be developed to scrutinize the anti/proangiogenic balance
within the malignant tumour, growth arrest, and adaptive
response to a suboptimal microenvironment [36]. Monitor-
ing disseminated and circulating tumour cells is the first
step towards better diagnosis. However, the large number
of patients that survive with disseminated tumour cells in
the bone marrow indicates the need to identify additional
molecular factors which characterize the microbiology of
disseminated cells [37].
Consequently, the future of targeted cancer treatment to
manage disseminated disease probably lies in the ability to
induce cell kill of dormant tumour population, to reprogram
malignant cells into growth arrest, and to develop biomarkers
to indicate the state of dormancy (rather than informing
about tumour recurrence).
3.4.1. Normal Tissue Radiosensitivity (RS). Variable radiosen-
sitivity of individual patient may explain recurrent cancer as
well as normal tissue damage in external beam radiotherapy.
Radiosensitivity could be a double-edged sword: if patients
range from high to low radiosensitivity, then extreme tissue
response is seen for the former and poor tumour control
in the latter. If the reasonable assumption is made that
all cells in the body, including cancer cells, have the same
genetic RS, then the cancer would be controlled by lower
and safe doses. However, the opposite effect will also be
true. Low RS means that higher but safe doses are needed
to control the cancer. Pretesting of patient RS may need to
be introduced as an important part of the dose planning
strategy.
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3.5. Healthy Tissue Protection. Healthy tissue protection and
reduction of treatment-related side effects are other impor-
tant considerations for the future. Chemotherapy as well as
targeted agents needs to be customized, since the same drug
and dosage can have minimal normal tissue toxicity in one
patient and be lethal to the other. It is suggested that single
nucleotide polymorphism (SNP) is a viable technique to be
used for the prediction of adverse events on an individual
basis and will undergo further research to be clinically
validated [30].
Patients have variable radiosensitivity, such that those
with high values will be overdosed for normal tissue and
those with low values will be underdosed for tumour control.
Adjustment to the intrinsic patient’s radiosensitivity could
be a far more important factor than improved dose delivery
systems. As such, radiosensitivity assays need to be developed
which could become an essential part of the patient workup
before radiotherapy.
More in-depth studies are needed regarding low doses of
radiation and their potential hormetic effect on healthy tissue.
Bystander effects induced by low doses of radiation to healthy
tissue surrounding the target and the consequential adaptive
response to radiation have gained interest and initiated
translational research from basic to preclinical studies. There
is growing evidence suggesting the potential role of low dose
irradiation in clinical settings. Bystander effects are expected
to have an impact on systemically targeted therapies; however
the limitation of existing dosimetric methods to describe
dose-response relationships of various cell lines at low doses
makes it difficult to assess the extent of cellular effects outside
the treated area.
4. Conclusions
The future of radiation oncology technology lies in its fusion
with biology. Otherwise, it is hard to see any major develop-
ments in the near future with respect to new technologies or
even the need formore expensive equipment.The last decades
have seen major advances in cancer imaging and external
beam therapy, and such investments have already paid off
in terms of achieving improved local control. However, they
are not matching the current needs in the management
of cancer. These needs centre on the control of systemic
disease by systemic treatment. Chemotherapy has fallen
short here. The fusion of biological targeting and high LET
radiation may well be our best hope (although there is little
evidence that funding agencies and “peer” reviewers share
that opinion). Therefore, biology-driven clinical trials are
expected to prevail hand in hand with the development of
new targeted agents.
Based on the above-reasoned problems and possible
solutions, the focus of future cancer control andmanagement
should be on the following.
(i) TAT: immunotherapy of cancer cells using high LET,
short range alphas and TAVAT.
(ii) Knowledge of molecular changes in cancer which can
lead to the design of therapies that target proliferation
and survival of cancer cells within a tumour as well
as in the surrounding tumour microenvironment
(i.e., development of genetically informed cancer
medicine).
(iii) The complexity of molecular interactions within and
among cancer cells, and between cancer cells and
normal cells, which will require refinement of multi-
agent treatment approaches against cancer.
(iv) Molecular diagnostics: development of tests that
will determine mutated genes in a patient’s tumour,
tumour expressedmolecules that can be targeted, and
the overall mutational gene expression profiles that
can predict a response to the treatment.
(v) Individualised patient treatments: treatments will
have to be modified depending on the molecular pro-
file of a particular tumour. For each patient the opti-
mal match between the tumour and therapeutic reg-
imen will be identified based on biological/genetical
information.
(vi) Healthy tissue protection with low doses of radiation
by utilizing potential hormesis and bystander effects.
Cancer may be ultimately controlled by genetic antisense
techniques that find and cancel out genetic aberrations with-
out causing any complications. However, this ideal objective
continues to elude us and, in the meantime, we need to apply
less ideal techniques to improve prognosis.
Nevertheless, the majority of the world’s populations are
a long way from curative cancer. Their needs call for a
new paradigm that brings palliative cancer therapy to the
rural populations. The cost-benefit of such centers is readily
apparent. They can also become centers for cancer screening
and ultimately upgraded for curative therapy.
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